Cut Down Influenza A with Sequivity(R) IAV-S NA

Pfizer Suspends Sale of Suvaxyn PCV2 Vaccine

April 28, 2010 — 

In a letter (reprinted below) to veterinarians dated April 28, 2010, Pfizer Animal Health announced a voluntary decision to temporarily suspend future sales of Suvaxyn PCV2 Vaccine as a result of an internal study which found inconsistency in the inactivation process. Following is the complete text of the letter from Dr. Steve Sornsen of Pfizer Animal Health.

We know you have a choice when it comes to circovirus vaccines, and Pfizer Animal Health is dedicated to supplying you with a safe, reliable and efficacious product.

We are committed to keeping you informed, and we wanted to let you know Pfizer Animal Health has voluntarily and temporarily suspended future sales of Suvaxyn PCV2 Vaccine, the legacy Fort Dodge Animal Health porcine circovirus vaccine. While this decision is effective today, product currently in your operation and/or the distribution channel has met the standards set by the United States Department of Agriculture (USDA) and may be used.

There are some key things to keep in mind regarding this voluntary action. Our decision to temporarily suspend sales is not the result of any reports of a lack of product efficacy or adverse events in vaccinated pigs. Rather, we took this step after reviewing interim results from a rigorous internal study of the inactivation process that suggested inconsistent inactivation of the virus in Suvaxyn PCV2 across production lots. We believed it was prudent to voluntarily stop sales of this product until we are able to review the final study results.

Pfizer Animal Health is committed to excellence and continuous improvement. We value your business and are dedicated to providing you with the highest standards possible. We strive to provide you with the sales and technical support you have come to expect from us.

Please contact your Pfizer Animal Health representative if you have questions.

Regards,
Dr. Steve Sornsen & Gloria Basse